Inflammatory bowel disease Venous thromboembolism Drug COLON-CANCER Stricture MARKER Intestinal crypts Monitoring Small molecules Resistance Colorectal cancer Colibactin and lipids Rituximab plus chlorambucil Bacteria Immune cells Clinical guidelines HIV Microbiote Gene methylation Epigenetics Algorithm Cost effectiveness Crohn’s disease MICROBIOTA IBD Dysbiose Survival Colon Ulcerative colitis Upper gastrointestinal tract DNA methylation Biomarker Microbiota Disability Rituximab Genes Original Article Clinical Surgery IL12 Primary sclerosing cholangitis Colectomy Inhibitor Vedolizumab Effectiveness RISK CARCINOGENESIS MORTALITY Gene expression Kidney diseases IL23 Bactéries Eradication Ustekinumab Immunosuppressant Contraindication Crohn's disease Anti-TNF Inclusion Tuberculosis Tailored therapy Maintenance therapy Helicobacter pylori Inflammatory Bowel Diseases Patients experience Dysbiosis Acceptability MALT Méthylation 18 FDG-PET/CT Over 80s T1118 translocation Neoadjuvant chemotherapy Cancer Therapeutics Epigénétiques Parvimonas micra Colon cancer Gènes PCR Disease progression Disease Progression Colonic epithelial primary cells Alkylating agents Anti-TNF agents Patient-reported outcome DNA METHYLATION Inflammatory bowel diseases Eligibility Fecal microbiota Biologics Colorectal cancer Endoscopic treatment Heart disease risk factors Consensus Methylation Résistance Thérapie ciblée Screening Cell adhesion Safety Clinical trial